LEO Pharma

New General Manager appointed to lead LEO Pharma across the Nordic region

Share
Klaus Abel arrives to take the regional helm of the global medical dermatology leader

April 30, Malmo, Sweden: LEO Pharma, a global leader in medical dermatology, has appointed Klaus Abel to take the helm as Managing Director for the Nordics.

Klaus Abel moves into the new role from Lundbeck where he was for 19 years. While at Lundbeck, he held senior roles in Global Marketing and in Commercial Operations in addition to Managing Director positions in Australia/New Zealand from 2007-2011 and Italy from 2016-2018.  In his new position, Klaus will report to Geraldine Murphy, Regional Vice President Cluster North Europe, Australia & New Zealand, LEO Pharma.

I am delighted to be taking charge of LEO Pharma in the Nordics at this exciting time for the organisation. I was attracted to LEO Pharma by its high ambitions, pioneering approach and clear focus on patients. Being a foundation-owned company LEO Pharma has no shareholders and is committed to reinvesting its profits into R&D. These aspects really stand out to me. I am inspired by the opportunity to improve the quality of life of the many people living with skin conditions by engaging all the stakeholders involved in providing care for people suffering from skin disease ranging from patients, policy makers, and healthcare professionals”, said Klaus Abel, Managing Director, LEO Pharma Nordics.

In terms of his approach to his new role, Klaus Abel added, “The organisation has declared its intent to help 125 million patients by 2025. It is an ambitious goal and I look forward to addressing the challenges ahead in bringing that strategy and vision to fruition. I intend to help build a best in class organisation and by increasing collaboration, championing cross functional collaboration in a true multi-channel integration to communication.

As Managing Director for the Nordics Organisation Klaus Abel will lead operations in Denmark, Sweden, Norway , Finland and Iceland. He will be responsible for driving LEO Pharma’s Dermatology business, developing talent and ensuring a successful implementation of LEO Pharma’s 2025 strategy. Klaus will also be part of the Cluster Europe North Australia New Zealand Leadership team.

Geraldine Murphy added, “It is a real pleasure to welcome Klaus Abel to LEO Pharma and the Cluster Leadership team. We very much look forward to working with him going forward to achieve our 2025 goals. We have a fantastic opportunity to draw on Klaus’s extensive knowledge and share experiences between our Cluster countries and collaborate closely together to be the preferred dermatology care partner. Our whole team is committed to helping people achieve healthy skin”.

Contacts

For further information please contact the Communications team:


Julie Wong, Head of Communications, LEO Pharma UK


T: +44 (0)7825918989 E: comms@leo-pharma.com

Images

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million. For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com

LEO Pharma Nordics is headquartered in Malmo, Sweden and comprises 55 people conducting commercial operations across both Dermatology and Thrombosis. The team spans Norway, Denmark, Sweden, Finland and Iceland and also has offices in Helsinki and Oslo.

For more information on careers within LEO Pharma Nordics please contact Lars Skouboe, Senior People Partner, E: LQUDK@leo-pharma.com

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.

LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)30.10.2023 10:00:00 CET | Pressemeddelelse

Subjects who completed the 16-week twice-daily treatment regimen of delgocitinib cream or cream vehicle in the phase 3 DELTA 1 or DELTA 2 trials were offered to immediately enroll into the 36-week DELTA 3 extension trial.1 The DELTA 3 trial evaluated the long-term safety of twice-daily as needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.1 The long-term safety profile of delgocitinib cream was consistent with previous results from the DELTA 1 and 2 trials. Patients who entered the DELTA 3 trial after receiving delgocitinib cream in the DELTA 1 and DELTA 2 trials maintained similar levels of symptom relief and treatment success over an additional 36-week treatment regimen.

LEO Pharma provides update on the development program for izuforant20.10.2023 09:43:02 CEST | Pressemeddelelse

The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint. As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical. LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye